Knowledge center
The place to find all the most innovative research and information on novel biologics and biosimilars.
June 03, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development of biosimilars, announced a collaboration with PSI CRO for the execution of a Phase 1 clinical study evaluating PB018, a proposed biosimilar to Ocrevus® (ocrelizumab), in patients with Multiple Sclerosis (MS).
The randomized, double-blind, parallel-group study is designed to compare the pharmacokinetics...
Latest news
Find out about all the latest developments of our portfolio and our partners products and other news from Polpharma Biologics.
June 03, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development of biosimilars, announced a collaboration with PSI CRO for the execution of a Phase 1 clinical study evaluating PB018, a proposed biosimilar to Ocrevus® (ocrelizumab), in patients with Multiple Sclerosis (MS).
The randomized, double-blind, parallel-group study is designed to compare the pharmacokinetics...
May 22, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur . Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil....
December 23, 2025 –Polpharma Biologics is pleased to acknowledge the recent announcement of Bioeq AG, our joint venture, regarding the licensing, supply, and commercialization agreement with Zydus Lifesciences Ltd. for NUFYMCO® (biosimilar ranibizumab), an interchangeable biosimilar to Lucentis®, in the United States.
This strategic collaboration underlines the strength and expertise of Polpharma...
December 10, 2025 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases...
Downloads
You can find all the latest presentations, brochures and fact sheets below covering our solutions and portfolio.
Polpharma Biologics S.A. is required to prepare and publish information on the executed tax strategy in order to fulfill the obligation set forth in Article 27c paragraph 1 in connection with Article 27b paragraph 2 points 1 and 2 of the Corporate Income Tax Act of February 15, 1992. We invite you to read the document.
This Code of Conduct is the first step to showing dedication to upholding continuous excellence in both business and ethical terms, and showing our care and dedication to products, clients and success.
Polpharma Biologics and the University of Warsaw have signed a cooperation agreement in an important step toward building the company’s international scientific cooperation platform.
